BioLineRx (BLRX) Cash from Operations Growth (3y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 37.40% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 16.64% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -7.60% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 34.32% |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | 17.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.42% |
| Sep 30, 2025 | 37.63% |
| Jun 30, 2025 | 69.58% |
| Mar 31, 2025 | 22.59% |
| Dec 31, 2024 | -16.09% |
| Sep 30, 2024 | -25.14% |
| Jun 30, 2024 | -18.39% |
| Mar 31, 2024 | -31.33% |
| Dec 31, 2023 | 42.91% |
| Sep 30, 2023 | -21.86% |
| Jun 30, 2023 | -20.27% |
| Mar 31, 2023 | -5.96% |
| Dec 31, 2022 | -1.53% |
| Sep 30, 2022 | -12.06% |
| Jun 30, 2022 | 0.81% |
| Mar 31, 2022 | -6.52% |
| Dec 31, 2021 | -2.29% |
| Sep 30, 2021 | 5.87% |
| Jun 30, 2021 | -3.09% |
| Mar 31, 2021 | 2.91% |
| Dec 31, 2020 | 4.94% |
| Sep 30, 2020 | 4.17% |
| Jun 30, 2020 | -9.72% |
| Mar 31, 2020 | -21.11% |
| Dec 31, 2019 | -9.95% |
| Sep 30, 2019 | -27.42% |
| Jun 30, 2019 | -25.48% |
| Mar 31, 2019 | -3.37% |
| Dec 31, 2018 | -17.27% |
| Sep 30, 2018 | -16.16% |
| Jun 30, 2018 | -19.23% |
| Mar 31, 2018 | -25.21% |
| Dec 31, 2017 | -9.83% |
| Sep 30, 2017 | -24.21% |
| Jun 30, 2017 | 1.00% |
| Mar 31, 2017 | -3.81% |
| Dec 31, 2016 | -3.20% |
| Sep 30, 2016 | 11.66% |
| Jun 30, 2016 | 19.37% |
| Mar 31, 2016 | 7.35% |